Sorrell v. IMS health: Issues and opportunities for informaticians

Journal of the American Medical Informatics Association

Volumn 20, Issue 1, 2013, Pages 35-37

  Petersen, Carolyn ^a   DeMuro, Paul ^b   Goodman, Kenneth W ^c   Kaplan, Bonnie ^d  

^a MAYO CLINIC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; COURT; DATA BASE; DATA PROCESSING; DOCTOR PATIENT RELATION; DRUG COST; DRUG MARKETING; FREEDOM; HEALTH INSURANCE; HUMAN; INFORMATION SCIENCE; INFORMED CONSENT; MEDICAL ETHICS; PRESCRIPTION; PUBLIC HEALTH; SAFETY;

CONFIDENTIALITY; DATA MINING; DRUG INDUSTRY; DRUG PRESCRIPTIONS; ELECTRONIC HEALTH RECORDS; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT; HUMANS; INFORMATION DISSEMINATION; MARKETING; PHARMACY SERVICE, HOSPITAL; SUPREME COURT DECISIONS; UNITED STATES; VERMONT;

EID: 84871886646     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2012-001123     Document Type: Article

References (32)

1. Institute of Medicine Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2007.
2. Greene JA. Pharmaceutical marketing research and the prescribing physician. Ann Intern Med 2007;146: 742-8.
3. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283: 373-80.
4. Code of Federal Regulations Part 164.514. http://www.gpo.gov/fdsys/pkg/CFR-2002-title45-vol1/pdf/CFR-2002-title45-vol1-sec164-514.pdf (accessed 13 May 2012).
5. Vermont General Assembly. Prescription confidentiality law. Montpelier, VT: Vermont General Assembly. http://www.leg.state.vt.us/statutes/fullsection.cfm? Title=18&Chapter=091&Section=04631 (accessed 5 May 2012).
6. IMS Health, Inc. v. Sorrell, 631 F. Supp. 2d. 434 (D.Vt.2009).
7. IMS Health, Inc. v. Sorrell, 630 F.3d 263 (2d Cir. 2010).
8. IMS Health, Inc. v. Mills, 616 F.3d 7 (1st Cir. 2010).
9. IMS Health, Inc. v. Ayotte,550 F.3d 42 (1st Cir. 2008).
10. Woodward C. Data-mining case tests boundaries of medical privacy. Can Med Assoc J 2011;183: E509-10.
11. Central Hudson Gas & Electric Corp. v. Public Service Commission of New York, 447 U.S. 557 (1980).
12. Sorrell v. IMS Health, 131 SCt 2653 (2011).
13. Post R. Prescribing records and the first amendment-New Hampshire's data-mining statute. N Engl J Med 2009;360: 745-7.
14. Post R. The constitutional status of commercial speech. UCLA Law Rev 2000;48: 1-57.
15. American Medical Association. AMA program offers physicians a choice when it comes to prescribing data. Chicago, IL: American Medical Association. http://www.ama-assn.org/resources/doc/dbl-public/pdrp-qa-final.pdf (accessed 5 May 2012).
16. Grande D, Asch DA. Commercial versus social goals of tracking what doctors do. N Engl J Med 2009;360: 747-9.
17. Gostin LO. Marketing pharmaceuticals: a constitutional right to sell prescriber-identified data?. JAMA 2012;307: 787-8.
18. Outterson K. Higher first amendment hurdles for public health regulation. N Engl J Med 2011;365: e13.
19. Mello MM, Messing NA. Restrictions on the use of prescribing data for drug promotion. N Engl J Med 2011;365: 1248-54.
20. Drazen JM. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med 2005;352: 1131-2.
21. Okie S. Raising the safety bar-the FDA's coxib meeting. N Engl J Med 2005;352: 1283-5.
22. Steinman MA, Harper GM, Chren MM, et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med 2007;4: 743-51.
23. Topol EJ. Nesiritide-not verified. N Engl J Med 2005;353: 113-16.
24. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004;24: 978-86.
25. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297: 308-11.
26. Hartung DM, Evans D, Haxby DG, et al. Effect of drug sample removal on prescribing in a family practice clinic. Ann Fam Med 2010;8: 402-9.
27. Caudill TS, Johnson MS, Rich EC, et al. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996;5: 201-6.
28. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension. JAMA 2004;291: 1850-6.
29. Katz D, Caplan AL, Merz JF. All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth 2010;10: 11-17.
30. Orentlicher D. Prescription data mining and the protection of patients' interests. J Law Med Ethics 2010;38: 74-84.
31. California HealthCare Foundation. National Consumer Health Privacy Survey 2005 executive summary. Oakland, CA: California HealthCare Foundation. http://www.chcf.org/~/media/MEDIA%20LIBRARY%20Files/PDF/C/PDF%20ConsumerPrivacy2005ExecSum.pdf (accessed 5 May 2012).
32. Henney JE. Safeguarding patient welfare: who's in charge?. Ann Intern Med 2006;145: 305-7.